F. Mirshahi

发表

Oncostatin M induces procoagulant activity in human vascular smooth muscle cells by modulating the balance between tissue factor and tissue factor pathway inhibitor

J. Soria, C. Soria, A. Tedgui, 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models.

J. Soria, C. Soria, Hong Li, 2000, Thrombosis research.

Inhibition of endothelial cell migration by cerivastatin, an HMG‐CoA reductase inhibitor: contribution to its anti‐angiogenic effect

J. Soria, C. Soria, L. Vincent, 2001, FEBS letters.

Cerivastatin, an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, Inhibits Endothelial Cell Proliferation Induced by Angiogenic Factors In Vitro and Angiogenesis in In Vivo Models

P. Opolon, J. Soria, C. Soria, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Induced by Angiogenic Factors In Vitro and Angiogenesis Cerivastatin , an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase , Inhibits

P. Opolon, J. Soria, C. Soria, 2002 .

Immunochemical detection of the mineralocorticoid receptor in rat brain.

M. Agarwal, W. Rostène, M. Mirshahi, 1993, Neuroendocrinology.

The role of fibroblasts in organization and degradation of a fibrin clot.

J. Soria, C. Soria, B. Azzarone, 1991, The Journal of laboratory and clinical medicine.

Fibrinogen: A Vascular Risk Factor, Why?

J. Soria, C. Soria, J. Vannier, 2001 .

Properties of the mineralocorticoid receptor immunopurified from bovine kidney.

M. Pagano, G. Lázár, M. Agarwal, 1994, Biochemical pharmacology.

Evidence for receptor-mediated mineralocorticoid action in rat osteoblastic cells.

P. Marie, M. Agarwal, A. Jullienne, 1996, The American journal of physiology.

Cyclooxygenase‐2 activity is necessary for the angiogenic properties of oncostatin M

Hong Li, J. Soria, C. Soria, 1999, FEBS letters.